Pfizer (NYSE: PFE), with his partner BioNTech (NASDAQ: BNTX), en Modern (NASDAQ: MRNA) are undoubtedly the clear leaders in the COVID-19 market. Some Americans are already receiving the vaccines from the companies and many more are waiting for vaccination.
But are there any shares that could win the COVID-19 vaccine race? Hierin Motley Fool Live a video recorded on December 18, 2020, Corinne Cardina, head of health care and cannabis, and author Keith Speights of Fool.com discuss two stocks that may look like the turtle in Aesop’s famous fable about the turtle and the hare .
Corinne Cardina: Let’s take some questions about Slido. James would like to know which companies are currently working on vaccines that match the doctor’s proposals. Keith, can you talk about maybe one or two of the turtle businesses that can finally start and really help with the pandemic that is not called Moderna, Pfizer and BioNTech?
Keith Speights: Certainly. Well, dr. Gellin, for example, mentioned single-dose vaccines. Well, the leader would be at the front Johnson & Johnson (NYSE: JNJ).
Johnson & Johnson is developing a single-dose vaccine. J&J said they would announce the efficacy results in January and hoped to be able to submit emergency use permits and hopefully receive them in February. So this is one vaccine that will hopefully be on the way soon and it is a single dose vaccine. I mentioned earlier that I am very interested to see what the effectiveness of J&J is. I really hope this is at least in the ballpark of what we saw with Pfizer and Moderna. It is therefore very important to look at.
Then there’s another company I called the dark horse in the race, Arcturus Therapeutics (NASDAQ: ARCT), ARCT is the tick there. Arcturus also has a single dose of vaccine, and the twist with that is that it is also a messenger RNA vaccine, just like the vaccine from Pfizer and Moderna. We have already seen the safety and efficacy profile of two different mRNA vaccines and they both look good, so I think it’s good for Arcturus’ chances of having good safety and efficacy results for the vaccine as well.
Again, this is a single dose, they are working on a lyophilized version of it that they plan to start in the late stages, hopefully pretty soon. This will help them to meet some of the requirements for cold storage. It therefore marks a number of subjects that dr. Called Gellin. So these were some companies that are being clinically tested, which I think have a lot of promising vaccines, if all goes well.